Value through Innovation27 July 2016

Clinical Study Results

  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.10
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase II
    Study Title

    A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (25 µg salmeterol), administered as the xinafoate salt from a hard polyethylene capsule via the HandiHaler® 2, and Serevent® Diskus® (50 µg salmeterol) in patients with chronic obstructive pulmonary disease (COPD)

    Study Document Trial synopsis 1184.10_DR english
  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.12
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiortopium bromide + Salmeterol
    Lab Code
    Clinical Phase II
    Study Title

    A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (12.5 µg, 25 µg and 50 µg salmeterol), administered as the xinafoate salt from hard polyethylene capsules via the HandiHaler® 2, and Serevent® Diskus® (50 µg salmeterol) in patients with chronic obstructive pulmonary disease (COPD)

    Study Document Trial synopsis 1184.12_DR english
  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.13
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, double-blind, crossover efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder in the morning (PE Capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder in the morning (gelatine capsule via Spiriva® HandiHaler®), Salmeterol (50 µg) Multi-Dose Powder Inhaler in the morning and evening and the free combination Tiotropium (18 µg) Inhalation Powder in the morning (gelatine capsule via Spiriva® HandiHaler®) plus Salmeterol (50 µg) Multi-Dose Powder Inhaler in the morning and evening following chronic administration (6-week treatment periods) in patients with COPD

    Study Document Trial synopsis 1184.13_DR english
  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.14
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase III
    Study Title

    A 24-week (+ 24 week extension) placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and FDC Tiotropium/Salmeterol plus Salmeterol in COPD patients

    Study Document Trial synopsis 1184.14 english
  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.15
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase III
    Study Title

    A 24-week (+ 24 week extension) placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and FDC Tiotropium/Salmeterol plus Salmeterol in COPD patients

    Study Document Trial synopsis 1184.15 english
  • Tiotropium bromide + Salmeterol - Healthy
    Clinical Study Number 1184.17
    Study Indication Healthy
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase I
    Study Title

    A randomised, open-label three-way crossover study to evaluate the pharmacokinetics of salmeterol after inhalation of a 25 µg and 50 µg single dose (inhalation powder, hard PE capsule for HandiHaler®2) and a 50 µg single dose (Serevent® Diskus®) in healthy male volunteers

    Study Document Trial synopsis 1184.17_DR english
  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.9
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase II
    Study Title

    A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of tiotropium inhalation powder (5 µg and 10 µg), administered as the bromide salt from hardpolyethylene capsule via the HandiHaler® 2, and Spiriva® HandiHaler® (18 µg tiotropium) in patients with chronic obstructive pulmonary disease (COPD).

    Study Document Trial synopsis 1184.9_DR english
  • Tiotropium bromide + Salmeterol - Healthy
    Clinical Study Number 1184.11
    Study Indication Healthy
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase I
    Study Title

    A randomised, open-label four-way crossover study to evaluate relative bioavailability of tiotropium and salmeterol after inhalation of a fixed combined single dose (7.5 µg tiotropium, 25 µg salmeterol, inhalation powder, hardcapsule, HandiHaler®2), a free combined single dose of 18 µg tiotropium[Spiriva® HandiHaler®] and 50 µg salmeterol [Serevent® Diskus®], a single dose of 50 µg salmeterol (Serevent® Diskus®) and a single dose of 18 µg tiotropium (Spiriva® HandiHaler®) in healthy male volunteers

    Study Document Trial synopsis 1184.11_DR english
  • Tiotropium bromide + Salmeterol - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1184.24
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium bromide + Salmeterol
    Generic Name Tiotropium bromide + Salmeterol
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of FDC Tiotropium/Salmeterol,Tiotropium, Salmeterol and a free combination of Tiotropium plus Salmeterol following 4-week treatment periods in patients with COPD.

    Study Document Trial synopsis 1184.24 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.